During the COVID pandemic, the vaccine approval process went from eight years to a few months. In addition, the FDA has used several expedited approval pathways, starting in the 1990s with HIV treatments and continuing today. On the next two episodes, Tom talks with two leading experts on these various approval pathways, what medications are on the approval fast track, and other considerations regarding expedited approval today.
Moderator:Tomas Villanueva, DO, MBA, FACPE, SFHMSenior Principal, Clinical Operations and Quality
During the COVID pandemic, the vaccine approval process went from eight years to a few months. In addition, the FDA has used several expedited approval pathways, starting in the 1990s with HIV treatments and continuing today. On the next two episodes, Tom talks with two leading experts on these various approval pathways, what medications are on the approval fast track, and other considerations regarding expedited approval today.
Moderator:
Tomas Villanueva, DO, MBA, FACPE, SFHM
Senior Principal, Clinical Operations and Quality
Vizient
Guests:
Jeni Hayes, PharmD, MSPharm, BCPS
Senior Clinical Manager, Pharmacy Outcomes
Center for Pharmacy Practice Excellence
Vizient
Steven Lucio, PharmD, BCPS
Senior Principal, Pharmacy Solutions
Center for Pharmacy Practice Excellence
Vizient
Show Notes:
[01:32] Vaccine approval path before and after COVID
[02:59] Rationale for accelerated approval; reducing preapproval research
[05:14] Examples of expedited approval recently – reducing the eight-year duration
[07:32] Rundown of various approval routes
Links | Resources:
To contact Modern Practice: modernpracticepodcast@vizientinc.com
Steven’s email: steven.lucio@vizientinc.com
Jeni’s email: jeni.hayes@vizientinc.com
FDA’s accelerated approval update page: Click here
Vizient Pharmacy Market Highlights – Dec. 2022: PMO322_PharmacyMarketOutlook_Highlights.pdf
Subscribe Today!
Apple Podcasts
Amazon Podcasts
Android
Google Podcasts
Spotify
Stitcher
RSS Feed
View more
